Systematic
reviews
Systematic
reviews
Controlled temperature chain for vaccination in low- and
middle-income countries: a realist evidence synthesis
Christopher P Seaman,a Anna-Lea Kahn,b Debra Kristensen,c Robert Steinglass,d Dijana Spasenoska,e Nick Scotta
& Christopher Morganf
Objective To evaluate the evidence describing how the controlled temperature chain approach for vaccination could lead to improved
equitable immunization coverage in low- and middle-income countries.
Methods We created a theory of change construct from the Controlled temperature chain: strategic roadmap for priority vaccines 2017–2020,
containing four domains: (i) uptake and demand for the approach; (ii) compliance and safe use of the approach; (iii) programmatic efficiency
gains from the approach; and (iv) improved equitable immunization coverage. To verify and improve the theory of change, we applied a
realist review method to analyse published descriptions of controlled temperature chain or closely related experiences.
Findings We evaluated 34 articles, describing 22 unique controlled temperature chain or closely related experiences across four World
Health Organization regions. We identified a strong demand for this approach among service delivery providers; however, generating an
equal level of demand among policy-makers requires greater evidence on economic benefits and on vaccination coverage gains, and use
case definitions. Consistent evidence supported safety of the approach when integrated into special vaccination programmes. Feasible
training and supervision supported providers in complying with protocols. Time-savings were the main evidence for efficiency gains,
while cost-saving data were minimal. Improved equitable coverage was reported where vaccine storage beyond the cold chain enabled
access to hard-to-reach populations. No evidence indicated an inferior vaccine effectiveness nor increased adverse event rates for vaccines
delivered under the approach.
Conclusion Synthesized evidence broadly supported the initial theory of change. Addressing evidence gaps on economic benefits and
coverage gains may increase future uptake.
Introduction
In many low- and middle-income countries, standard cold
chain (2–8 °C) capacity for vaccine delivery is often restricted
or unreliable,1 leading to vaccine stock-outs, increasing equipment costs and limiting the availability of vaccines in remote
areas. During outreach campaigns, the use of carrier boxes and
ice-packs to maintain a cold chain right to the point of vaccine
administration increases time and cost, and risks vaccine damage by freezing through incorrectly placing vaccines in direct
contact with ice-packs. A solution is the controlled temperature
chain approach, a vaccine management protocol endorsed
by the World Health Organization (WHO), which leverages
the existing thermostability of certain vaccines to allow more
flexibility in service delivery.2 By providing a safe and simple
protocol for storage of selected vaccines at temperatures beyond
the standard cold chain, the controlled temperature chain has
the potential to substantially improve vaccination equity.3
For a vaccine to be used under a controlled temperature
chain, manufacturers must demonstrate to regulators that
exposure to temperatures ≥ 40 °C for a minimum three-days
single planned excursion neither impedes vaccine safety nor
effectiveness. Monitoring of exposures is mandated, requiring
both vaccine vial monitors to measure cumulative heat exposure and peak temperature threshold indicators to measure
instantaneous heat exposure. The controlled temperature chain
approach is currently recommended only for special vaccine
delivery strategies (e.g. births, school campaigns and outbreak
response), with three vaccines currently WHO-prequalified
for controlled temperature chain use. As of 2017, more than 4
million vaccines have been administered under this approach.2,4
The WHO Controlled temperature chain: strategic roadmap
for priority vaccines 2017–2020 provides a descriptive framework explaining how controlled temperature chain can lead to
greater, and more equitable, immunization coverage for eligible
vaccines.2 Here we use a realist review method to synthesize evidence from controlled temperature chain experiences to identify
key priorities for future research. We also establish what may be
needed to promote stakeholders’ interest for greater controlled
temperature chain uptake in low- and middle-income countries.
Methods
Initial theory of change
We first obtained the descriptions of how the controlled
temperature chain approach could lead to improved equitable immunization coverage from the Controlled temperature
chain: strategic roadmap for priority vaccines 2017–2020, with
descriptions supplemented from an associated commentary
Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia.
Immunization, Vaccines and Biologicals Department, World Health Organization, Geneva, Switzerland.
c
Bend, Oregon, United States of America (USA).
d
Mars Hill, North Carolina, USA.
e
Department of Social Policy, The London School of Economics and Political Science, London, England.
f
Jhpiego, Johns Hopkins University affiliate, Baltimore, USA.
Correspondence to Christopher P Seaman (email: chris.seaman@burnet.edu.au).
(Submitted: 11 December 2021 – Revised version received: 26 May 2022 – Accepted: 26 May 2022 – Published online: 22 June 2022 )
a
b
Bull World Health Organ 2022;100:491–502 | doi: http://dx.doi.org/10.2471/BLT.21.287696
491
Systematic reviews
Christopher P Seaman et al.
Controlled temperature chain for vaccination
Box 1. Key terms used to identify studies on controlled temperature chain for
vaccination
• “controlled-temperature chain” or “controlled temperature chain” or “out-of-the-cold-chain”
or “out-of-cold-chain” or “outside the cold chain” or “outside cold chain” or thermostable
• AND
• vaccine or vaccination or immuni$e or immuni$ation or HPV or OCV or Hepatitis B or Tetanus
or Birth Dose or MenAfriVac or Meningitis
piece.2,5 Once obtained, we articulated
these descriptions as a theory of change
following a previously published context–mechanism–outcome construct.6,7
To ensure representativeness and accuracy of the articulated theory of change
to source descriptions, we consulted the
WHO Controlled Temperature Chain
Working Group. Outcomes included
in the theory of change were limited to
implementation and excluded manufacturing considerations.
We commenced the evidence synthesis once a consensus on the initial
theory of change had been reached.
Evidence synthesis
Evidence search
We searched MEDLINE®, EMBASE®,
CINAHL and Web of Science (all databases) using the key terms presented
in Box 1, up to 7 April 2022. Targeted
online searches, reference combing and
contacting the WHO working group for
additional evidence complemented the
search. We applied no language restrictions.
Studies using either controlled temperature chain or controlled temperature
chain-relevant approaches (e.g. planned
storage of non-controlled temperature
chain-approved vaccines beyond the
standard cold chain) were eligible for
inclusion. We excluded perspectives
from key stakeholders (e.g. commentary
pieces, laboratory-based studies) or studies that were not based on an implementation experience. Economic modelling
studies were considered eligible if costs
were ascertained from a controlled
temperature chain or controlled temperature chain-relevant implementation
experience.
Two authors subjectively evaluated
whether studies provided evidence on at
least one aspect in the theory of change
construct and the rigour of the evidence.
To assess rigour in studies with sufficient
methodological description, we used
three quality assessment checklists;
(i) Cochrane Effective Practice and Organization of Care for quantitative studies;8
492
(ii) Critical Appraisal Skills Programme
for qualitative studies;9 and (iii) Consensus on Health Economic Criteria list
for economic evaluations.10 Across all
checklists, we classified quality of evidence on a three-tier (yes/no/unclear or
high quality/low quality/unclear) scale.
Extraction and synthesis
Data extraction was thematic, guided
by context–mechanism–outcome constructs within the initial theory of
change, and supplemented by relevant
categories from the WHO Supporting
the Use of Research Evidence checklist.11
We did not apply any saturation threshold. Two authors initially extracted the
text verbatim from source documents,
and subsequently aggregated the text to
identify key overlapping or contrasting
concepts.
We employed narrative methods for
the synthesis,12,13 allowing for aggregation
of quantitative and qualitative findings.
Two authors completed the synthesis,
then it was cross-checked by other authors for consensus. Levels of supporting
evidence for mechanisms and outcomes
were subjectively determined, informed
by quality and quantity of included
studies. Evidence was deemed strong if
supported by high-quality evidence and
results repeated across multiple experiences. The synthesis was iterative and
we revised the initial theory of change if
supported by identified evidence.
The synthesis was adherent with
reporting standards for realist syntheses 14 and, where applicable, preferred
reporting items for systematic reviews
and meta-analyses.15 We registered the
synthesis on OSF (https://osf.io/a3z6s).
Results
The initial theory of change shows that
due to the historic reliance on the standard cold chain, awareness of controlled
temperature chain and relevant use cases
are needed to drive demand and uptake
(domain 1). Once safely and effectively
implemented within special vaccination
activities (domain 2), controlled temperature chain would enhance efficiency
(domain 3) and equity of coverage (domain 4; Fig. 1).
Review of evidence
We identified 34 eligible articles, including 22 unique controlled temperature
chain or relevant implementation descriptions (Fig. 2).4,16–48 Most frequently
(14/34; 41%) articles covered hepatitis
B (HepB) birth dose descriptions,16–29
but implementations were limited to
the South-East Asia and Western Pacific
Regions. Approximately one quarter
of implementation experiences used a
controlled temperature chain-licensed
vaccine (6/22; 27%): four used meningitis
A conjugate vaccine,4,30–33 one used human papillomavirus (HPV) vaccine34 and
one used oral cholera vaccine.35 Although
not designated a priority vaccine for controlled temperature chain,2 a single oral
polio vaccine implementation study was
eligible for synthesis.36 Almost half the
experiences (10/22; 45%) were from the
African Region,4,30–34,36–40,42,44,45 while no
relevant experiences were identified in
the Eastern Mediterranean or European
Regions (Table 1).
Six articles had quality assessment
domains at a high risk of bias or with
an unmet criterion.20,22,28,33,38,41 Most included studies had one or more domains
where evidence quality was unclear.
Further details are available in the data
repository.49
Theory of change domain 1
Demand and uptake
The key context identified for the demand
and uptake of the approach was appreciation of disease burden and a need to overcome cold chain limitations to vaccinate
hard-to-reach populations. Appreciation
of these standard cold chain limitations
were reported in many implementation
experiences, 4,20–23,26,32,37,42 but by only
24% (6/25) of national stakeholders in a
survey assessing interest for controlled
temperature chain for prequalified HepB
vaccines.35 We anticipated vaccine damage due to cold chain failures (freezing or
heat exposure) to be a contextual driver
of controlled temperature chain demand.
While in two surveys, national and global
stakeholders saw utility of such approach
to avert these problems,41,46 vaccine damage as a driver of demand was only cited
in four unique implementations.16,17,21,34,36
Some evidence supported the awareness of controlled temperature chain as a
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
Systematic reviews
Controlled temperature chain for vaccination
Christopher P Seaman et al.
mechanism to drive demand and uptake
among policy-makers. Three surveys indicated that 72% (18/25) to 75% (21/28)
of national and global policy-makers
showed a demand for controlled temperature chain use.19,41,46 Awareness raised
through policy adaptations, including
WHO endorsement for controlled
temperature chain-relevant storage of
the HepB birth dose, predicated uptake
in two implementations.20,22 Awareness
via endorsement from implementation
partners was noted to influence uptake by
health ministries in oral cholera vaccine
and tetanus toxoid-containing vaccine
experiences.37,40
There was limited evidence on identification of credible and beneficial use
cases for controlled temperature chain
vaccines, a mechanism required to drive
sustained demand by policy-makers. We
identified a clearly defined use case for
meningitis A conjugate vaccine across
four unique experiences: campaigns in
remote sub-Saharan Africa with limited
or no access to a cold chain.4,30–33 For
other vaccines the evidence was emerging or yet to be determined. For example,
controlled temperature chain facilitated
self-administration of a second oral cholera dose or vaccination to be completed
alongside more traditional cholera
control strategies.35,38,40,42 We could not
identify agreed controlled temperature
chain use cases for the HepB vaccine
despite 10 controlled temperature chainrelevant implementations. 16–18,20–24,26–29
Even with a controlled temperature
chain-licensed vaccine and awareness of
relevant coverage barriers in HPV vaccination efforts,43,48 we only identified a
single implementation.34
For vaccines with no defined use
case, 20% (36/183) of respondents
across two surveys saw the controlled
temperature chain as a fall back mechanism for transient cold chain breaks.19,41
Sustained demand, via controlled temperature chain-licensure, varied across
controlled temperature chain-relevant
experiences; noted in three oral cholera
vaccine experiences but only in a single
HepB vaccine experience.22,38,40,42 In at
least four experiences, controlled temperature chain-relevant vaccine storage
enabled integration of vaccination into
existing health programmes. 24,28,29,40,42
However, fears of higher vaccine procurement costs, training feasibility and use
of controlled temperature chain leading
to poor cold chain practices dampened
stakeholders’ demand for the controlled
temperature chain.19,41,46
Theory of change domain 2
Safe and compliant use
Based on the evidence synthesis, we reframed this domain to focus on evidence
of safe and compliant controlled temperature chain implementation (Fig. 3).
Within the context of special vaccination programmes, presence of temperature exposure monitoring technologies
mediated safe and compliant vaccine use,
including when used by health volunteers
or by community members self-administering vaccines. 28,29,35,38,39 Ten studies
relied on vaccine vial monitors measur-
Fig. 1. Context–mechanism–outcome construct for the theory of change of the Strategic Roadmap for Priority Vaccines
Context
Theory of change domain 1
Theory of change domain 2
Theory of change domain 3
Theory of change domain 4
Demand and uptake of the
controlled temperature chain
Controlled temperature chain
used effectively and safely in
programmes
Improved efficiency of
vaccination programmes
Improved equitable
coverage
A history of reliance on standard
cold chain logistics; and a lack of
experience with vaccine use
outside the standard cold chain
Special vaccination programmes
(school campaign, outbreak
response and birth dose
vaccination)
Adequately trained vaccinators
working in special vaccination
programmes
Populations with restricted access
to vaccinations, or historically low
vaccination coverage
Awareness of relevant cold chain
constraints in different settings
Guidance and training provided
to vaccination workers on correct
controlled temperature chain
practices
No sourcing preparation or
conditioning of ice-packs reduces
the risk of vaccine freezing
Understanding of, and
compliance with, controlled
temperature chain protocols by
local vaccination workers
Awareness of the controlled
temperature chain as an available
intervention for relevant
vaccination programmes
Mechanism(s)
National policy-makers able to
identify use cases that would
benefit from the controlled
temperature chain, including use
alongside existing health
programmes
Outcome
Demand and uptake of controlled
temperature chain-licensed
vaccines
Understanding of, and
compliance with, controlled
temperature chain protocols by
local vaccination workers
Reduced dependence upon
peripheral cold chain capacity
Effort previously required for
transportation and maintenance
of cold chain redirected to
microplanning and vaccination
Reduced reliance on cold chain,
transport and lower staff burden
Evidence of safety and
effectiveness of ambiently stored
vaccines
Overall cost–effectiveness is
improved even with increased
vaccine commodity cost
The controlled temperature chain
used effectively and safely within
vaccination programmes
The controlled temperature
chain improves efficiency
of vaccination
(time and cost savings)
Improved equitable
vaccination coverage
Note: We derived this construct from descriptions contained in the Controlled temperature chain: strategic roadmap for priority vaccines 2017–2020.2 Downward
arrows indicate link of context–mechanism–outcome within each theory of change domain. Horizontal arrows link domains to each other within the overall
theory of change.
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
493
Systematic reviews
Christopher P Seaman et al.
Controlled temperature chain for vaccination
Fig. 2. Study selection for the realist synthesis on the evidence of controlled
temperature chain for vaccination in low- and middle-income countries
Theory of change domain 3
492 unique articles identified, through MEDLINE®,
EMBASE®, CINAHL® and Web of Science
Titles and abstracts of the identified articles screened
437 articles excluded
55 full-text articles assesed for eligibility
37 articles excluded:
• 6 economic modelling studies not based on an
implementation experience
• 10 commentaries without experience
• 10 reviews
• 5 articles reporting on laboratory-based or synthetic
experiences
• 4 articles lacked relevance
• 1 article unable to obtain full text
• 1 conference abstract with insufficient details
16 additional articles identified:
• 2 articles from targeted searches of search engines
• 4 articles from reference combing
• 10 articles provided by content experts
34 articles included
• 3 articles on the HPV vaccine
• 6 articles on the oral cholera vaccine
• 14 articles on HepB birth dose
• 2 articles on tetanus toxoid-containing vaccine
• 6 articles on the meningitis A conjugate vaccine
• 2 stakeholder survey articles
• 1 article on the oral polio vaccine
HepB: hepatitis B; HPV: human papillomavirus.
Note: Sutanto et al. described a controlled temperature chain-relevant experience using both the HepB
birth dose and the tetanus toxoid-containing vaccine.16
ing cumulative heat exposures as the sole
indicator of vaccine integrity.18–22,36,38–40,42
Five experiences used peak temperature
threshold indicators to measure instantaneous heat exposures,4,16,17,31,34 while
digital thermometers or comparison to
ambient temperatures were also used in
four experiences.22,23,36,47 In addition, use
of monitoring forms to track vaccine use
and exposures over an implementation
was reported in four experiences.4,33,34,36
Strong and consistent evidence
demonstrated that training of vaccinators
in safe and compliant use of controlled
temperature chain was feasible and nononerous. Training was often less than
a day in duration or integrated among
other programmatic activities.16,22,29,33,34,47
Training encompassed vaccine vial monitor interpretation, controlled temperature chain protocol awareness and use of
peak temperature threshold indicators.
While methodological rigour in evalu494
adversely affected other cold chain practices; however, we could only discern this
interpretation from two implementations.4,34
ation of training success varied across
experiences, and some protocols deviated from currently accepted controlled
temperature chain standards,16,17,36,42 good
compliance was consistently reported
across all professional levels. Supervision, facilitated by implementation
partners4,34,42 or project managers,28,29 was
feasible and important for maintenance
of correct practices and maximizing
benefits of the controlled temperature
approach. Examples included provision
of real-time feedback to maximize efficiency during a meningitis A conjugate
vaccine implementation in Benin,4 and
identification and rectification of unsafe
vaccine disposal by health volunteers
in Papua New Guinea.29 Furthermore,
supervision and training were seen as
potential mechanisms to catalyse use
of the controlled temperature approach
where permitted in Kiribati.24 Further,
no evidence suggested that the approach
Programme efficiency
The driver of improving programme
efficiency and timeliness was existing
inefficiencies in maintaining a standard
cold chain for special vaccination programmes. Challenges and costs associated with providing cold chains for timely
service delivery were described in studies
on meningitis A conjugate vaccine and
oral cholera vaccine experiences.4,30,31,40,42
Controlled temperature approaches were
considered a more efficient alternative,
linking to a demand for uptake. This
feedback loop – efficiency of controlled
temperature chain to overcome cold
chain challenges leading to increased
demand – is now reflected within the
revised theory of change (Fig. 3).
This feedback loop was also supported by some evidence of a vaccinator
preference (implying a demand) for controlled temperature chain or controlled
temperature chain-relevant approaches
over the standard cold chain. This preference was driven by efficiency related
mechanisms, namely reported timesavings from no longer having to prepare,
carry and replenish ice-packs during
outreach vaccination efforts.4,34,36 A controlled temperature chain was generally
evaluated as not adding any additional
complexity to service provision, except
in one experience where the increased
frequency of vaccine replenishment was
reported to increase workload.20
Little evidence existed in quantifying reduced costs of vaccination under
the approach. Two implementations
using HepB birth doses showed controlled temperature chain-relevant use
of compact pre-filled auto-disable devices was more efficient than standard
cold chain approaches, but savings were
driven by devices-mediated task-shifting
and waste reduction and could not be
directly attributed to the controlled
temperature chain.18,28 As prequalified
controlled temperature chain vaccine
experiences were limited, we could not
assess trade-offs between higher vaccine
costs and reduced cold chain costs, a
concern raised in interviews with key
stakeholders.19,41 Two studies estimated
credible cost savings within meningitis
A conjugate vaccine experiences, ignoring vaccine prices, under an assumption
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
Study
Location, WHO region
Vaccine
Sutanto et al., 199916
Indonesia, South-East Asia Region
Nelson et al., 200225
Indonesia, South-East Asia Region
HepB birth dose
and tetanus
toxoid-containing
vaccine
HepB birth dose
Levin et al., 200518
Indonesia, South-East Asia Region
HepB birth dose
PATH, 200527
China, Western Pacific Region
HepB birth dose
Hipgrave et al.,
200623
Huong et al., 200626
Viet Nam, Western Pacific Region
HepB birth dose
Viet Nam, Western Pacific Region
HepB birth dose
Wang et al., 200721
China, Western Pacific Region
HepB birth dose
Halm et al., 201036
Mali, African Region
Oral polio vaccine
Morgan et al., 201029
Papua New Guinea, Western
Pacific Region
HepB birth dose
Morgan et al., 201128
Papua New Guinea, Western
Pacific Region
HepB birth dose
Ciglenecki et al.,
201342
Wigle et al., 201348
Guinea, African Region
Oral cholera
vaccine
HPV vaccine
Juan-Giner et al.,
201437
Luquero et al., 201444
Regions of those interviewed not
stated
Chad, African Region
Guinea, African Region
495
Tetanus toxoidcontaining vaccine
Oral cholera
vaccine
Controlled temperature chain-relevant storage of compact pre-filled auto-disable devices
used to facilitate vaccination of pregnant women at home during antenatal visits
Seroconversion comparison between controlled temperature chain-relevant stored compact
pre-filled auto-disable devices and vaccines stored in the standard cold chain, measured
after completion of infant vaccination series
Effectiveness of controlled temperature chain-relevant stored compact pre-filled autodisable devices assessed, and health worker perceptions on controlled temperature chainrelevant storage gauged
Perspective of midwives who used controlled temperature chain-relevant stored compact
pre-filled auto-disable devices to deliver birth dose during home births in a rural setting
Economic evaluation of using controlled temperature chain-relevant stored compact prefilled auto-disable devices to deliver the birth dose to home births in remote villages
Coverage, timeliness and effectiveness of controlled temperature chain-relevant stored
vaccine compared with standard cold chain practices in a rural setting
Comparative immunogenicity after full vaccine series, with birth dose storage either
controlled temperature chain-relevant or in standard cold chain
Coverage, promptness and vaccine effectiveness of controlled temperature chain-relevant
stored birth dose compared with the standard cold chain in a rural setting
Coverage, timeliness and effectiveness of controlled temperature chain-relevant stored
vaccine compared with standard cold chain practices in a rural setting
Vaccine wastage levels measured, and vaccinator preference assessed, for outreach vaccine
delivery in a crossover intervention study comparing controlled temperature chain-relevant
storage versus standard practice
Assessment of coverage, acceptability and feasibility of controlled temperature chainrelevant stored compact pre-filled auto-disable devices to enable village health volunteers
to deliver birth doses during home births in a rural setting
Economic evaluation of controlled temperature chain-relevant stored compact pre-filled
auto-disable devices delivered by village health volunteers to deliver birth doses during
home births in a rural setting
Controlled temperature chain-relevant transportation and storage of vaccine vials for
outreach vaccination in a reactive campaign
Key informant interviews used to ascertain greatest barriers to vaccine delivery, including
potential barriers overcome by use of controlled temperature chain
Safety and effectiveness of controlled temperature chain-relevant stored vaccines compared
with the standard cold chain in a non-inferiority trial
Case–control study estimating vaccine effectiveness of controlled temperature chainrelevant transported and stored vaccine in a reactive campaign
Demand
and
uptake
Safe and
compliant
use
Efficiency
gains
Improved
equitable
vaccination
coverage
No
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
No
No
No
Yes
(continues. . .)
Systematic reviews
Tetanus toxoidcontaining vaccine
HepB birth dose
Contribution to theory of change domain
Controlled temperature chain for vaccination
Otto et al., 199917
Bolivia (Plurinational State of ),
Region of the Americas
Indonesia, South-East Asia Region
Quiroga et al., 199847
Brief summary
Christopher P Seaman et al.
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
Table 1. Summary of studies included in synthesis of the contribution of controlled temperature chain for vaccine to the theory of change
Location, WHO region
Lydon et al., 201445
Chad, African Region
Porta et al., 201440
South Sudan, African Region
Steffen et al., 201431
Benin, African Region
Zipursky et al., 20144
Benin, African Region
Kolwaite et al., 201622
Lao People's Democratic Republic,
Western Pacific Region
Côte d’Ivoire, African Region
Kouassi et al., 201633
Kristensen et al.,
201641
Li et al., 201724
Kiribati, Western Pacific Region
Mvundura et al.,
201730
Petit et al., 201719
Togo, African Region
Ladner et al., 201643
Grandesso et al.,
201838
Heyerdahl et al.,
201839
African and Western Pacific
Regions
Malawi, African Region
Malawi, African Region
Meningitis A
conjugate vaccine
Oral cholera
vaccine
Meningitis A
conjugate vaccine
Meningitis A
conjugate vaccine
HepB birth dose
Meningitis A
conjugate vaccine
N/A
HPV vaccine
HepB birth dose
Meningitis A
conjugate vaccine
HepB birth dose
Meningitis A
conjugate vaccine
HepB birth dose
Oral cholera
vaccine
Oral cholera
vaccine
WHO, 201834
Uganda, African Region
HPV vaccine
Khan et al., 201935
Bangladesh, South-East Asia
Region
Oral cholera
vaccine
Brief summary
Economic evaluation assessing incremental cost differences of using controlled temperature
chain instead of the standard cold chain in a vaccine campaign
Description of a reactive vaccine campaign where controlled temperature chain-relevant
storage and transportation of vials was used
Comparison of adverse event rates from controlled temperature chain and cold chain stored
vaccines, and average duration of controlled temperature chain assessed
Description of first prequalified controlled temperature chain vaccine experience, which
includes a survey of vaccination staff for perceptions of the approach
Pilot study evaluating total coverage, timeliness and acceptability of controlled temperature
chain-relevant storage compared with standard cold chain approach in two areas
Knowledge of controlled temperature chain practices among vaccination staff and
supervisors surveyed during a vaccine campaign
Stakeholders interviewed on their perspective towards thermostable vaccines, including the
use of a controlled temperature chain
Questionnaire of key stakeholders in vaccine implementations to identify programme
barriers, including those which could be overcome by a controlled temperature chainlicensed vaccine
Controlled temperature chain-relevant storage piloted in remote health facilities. Health
workers surveyed on perceived acceptability, feasibility and barriers of this approach
Comparative coverage of the vaccine in controlled temperature chain and standard cold
chain assigned areas evaluated using a cluster randomized survey
Controlled temperature chain-relevant storage of birth dose encouraged to help increase
coverage among home births
Economic evaluation of incremental supply chain costs for the vaccine when used in
controlled temperature chain compared with the standard cold chain during a campaign
Vaccination stakeholders questioned about interest, perceived benefits and willingness-topay for a controlled temperature chain-licensed vaccine
Controlled temperature chain-relevant storage of vaccine vials used to facilitate selfadministration of second dose in a remote population
In-depth interviews and focus groups used to investigate acceptability of controlled
temperature chain-relevant storage to facilitate self-administration of second dose in a
remote population
Pilot study comparing worker perceptions, coverage, vaccine wastage and efficiency of
vaccine under controlled temperature chain versus standard cold chain for a schoolbased campaign in a rural setting
Evaluation of coverage, safety and acceptability of controlled temperature chain-licensed
vaccines when used to facilitate self-administration of second dose at home
Contribution to theory of change domain
Demand
and
uptake
Safe and
compliant
use
Efficiency
gains
Improved
equitable
vaccination
coverage
No
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
No
No
No
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
No
Yes
No
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
(continues. . .)
Christopher P Seaman et al.
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
Breakwell et al.,
201720
Landoh et al., 201732
Six countries from the African,
American, South-East Asia and
Western Pacific Regions
19 countries from African,
American, European, South-East
Asia and Western Pacific Regions
Solomon Islands, Western Pacific
Region
Togo, African Region
Vaccine
Systematic reviews
Study
Controlled temperature chain for vaccination
496
(. . .continued)
Systematic reviews
Controlled temperature chain for vaccination
N/A
61 countries, 75% from African
Region
Mvundura et al.,
202146
Location, WHO region
Study
(. . .continued)
HepB: Hepatitis B; HPV: Human papillomavirus; N/A: not applicable (stakeholder perspective on the controlled temperature chain evaluated and was not limited to specific vaccines). WHO: World Health Organization.
Note: Relevant approaches refers to vaccine use beyond the standard cold chain with a non-controlled temperature chain-approved vaccine. More details are available in the data repository.49
No
No
Qualitative study of vaccination stakeholders as part of the Vaccine Innovation
Prioritisation Strategy, including questions on perceived benefits and use of controlled
temperature chain vaccines
Yes
No
Improved
equitable
vaccination
coverage
Efficiency
gains
Safe and
compliant
use
Demand
and
uptake
Vaccine
Brief summary
Contribution to theory of change domain
Christopher P Seaman et al.
that a proportion of cold chain costs
were avoided when using the controlled
temperature chain.30,45 However, a direct
comparison in one experience showed no
incremental cost differences between the
two approaches.30
Evidence supported two new mechanisms by which controlled temperature
chain enhanced vaccination efficiency
and timeliness. First, the approach enabled more rapid delivery of vaccination
to target populations.18,28,29,38,40,42 Second,
the approach was not associated with
any additional vaccine wastage when
compared with cold chain,30,36 and where
any measurable wastage of vaccines
stored beyond the cold chain occurred,
it resulted from stock management and
microplanning failures.20,34
We revised the key outcome for this
domain in two elements after evidence
synthesis (Fig. 3). Time-savings were
reported, but not quantified, while no
implementation study quantified cost
savings. Credible but theoretical cost
savings attributable to controlled temperature chain were extrapolated from
modelling;30,45 and where cost savings
were reported, causality could not be
disentangled from the use of compact
pre-filled auto-disable devices.18,28
Theory of change domain 4
Equitable vaccination coverage
The ability of the controlled temperature chain approach to improve equitable vaccination coverage was supported
by promising evidence; however, experiences designed to quantify coverage
gains were restricted to HepB birth vaccination.20–22,26,27 Coverage benefits varied by implementation setting: in Lao
People's Democratic Republic, coverage
gains were greatest for births in health
facilities;22 whereas in rural China, the
approach was most beneficial for timely
coverage of home births.21 In some studies, observed coverage gains due to the
approach were cited as motivation for
uptake in other experiences,20–22 forming a feedback loop between equitable
coverage gains and controlled temperature chain uptake. This feedback loop
is now reflected in the revised theory
of change (Fig. 3). Across controlled
temperature chain and controlled
temperature chain-relevant HPV, oral
cholera and meningitis A conjugate vaccine experiences, reported high levels of
coverage were unlikely to be achieved
unless vaccines were stored beyond the
cold chain.4,32,35,40
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
We found no evidence of the
approach increasing adverse event
rates or reducing vaccine effectiveness.17,19–21,23,31,36–38,44 Further, researchers
for two studies in Viet Nam hypothesized
that controlled temperature chainrelevant storage of the HepB birth dose
have enhanced immunogenicity due to
prevention of freezing.23,26
Discussion
We identified a credible evidence base
that broadly supported the initial theory
of change; however, synthesis identified some key refinements. Evidence
supported feasibility of safe controlled
temperature chain integration into
vaccination programmes, with robust
evidence showing complicit and safe use
by vaccinators. However, clearly defined
use cases for most controlled temperature
chain-eligible vaccines were lacking. Future research priorities to promote uptake
of controlled temperature chain approach
should include economic evaluations
and studies to quantify equitable coverage gains.
Meningitis A conjugate vaccine
delivery under the controlled temperature chain was only implemented in the
African Region, probably due to the fact
that the vaccine is designed for use in
the sub-Saharan meningitis belt.50 Implementations of controlled temperature
chain-relevant approach for the HepB
birth dose were limited to the Western
Pacific and South-East Asia regions. One
reason may be the prominence of vertical
transmission of HepB in these regions as
compared with the African Region,51 and
a generally low adoption and scale-up of
HepB birth dose in the African Region.52
Another reason may be national and regional frameworks endorsing controlled
temperature chain-relevant birth dose
use in Western Pacific and South-East
Asia regions,24,53 raising awareness and
promoting uptake. Policy-makers should
remain open to similar adaptations for
other eligible vaccines, especially given
available evidence on safe and compliant use.
Our synthesis identified robust
evidence supporting the safe integration
and compliant use of controlled temperature chain by vaccinators. Despite
stakeholder concerns about costs or
feasibility of training, evidence indicated
the training can be integrated into other
routine programme trainings or is of low
burden when completed in a stand-alone
497
Systematic reviews
Christopher P Seaman et al.
Controlled temperature chain for vaccination
fashion. Observed compliance with
protocols was high across a wide range
of health-education levels, including
community members and volunteers. In
addition, despite stakeholder concern,
no evidence suggested practice of the
approach led to miscreant cold chain
practices. Evidence on safe and compliant use should encourage policy-makers
to explore use cases where controlled
temperature chain is the only option,
such as storage of the HepB birth dose
in remote locations or self-administered
oral cholera vaccine. These use cases
could both generate a sustained demand
and facilitate more equitable, or timelier,
vaccination coverage.
One key refinement made to the
initial theory of change, shown as a
feedback loop, was that efficiency of
controlled temperature was driving
demand. Decision-makers thought the
approach overcame the problems of
maintaining the cold chain in challenging
circumstances and vaccinators preferred
the decreased workload compared with
standard cold chain. While few studies
described averted freeze damage due
to controlled temperature chain during
implementations, we note that freeze
damage is a common occurrence in many
cold chains and poorly recognized by
service providers,54–56 and performance
gains on this aspect may have gone
unreported in experiences. However,
policy-makers hesitated regarding the
potentially higher vaccine prices for
a prequalified controlled temperature
chain vaccine. We found no real-world
implementation evidence to counter
this hesitancy; rather, any evidence of
cost–effectiveness (derived through
gains in vaccine delivery efficiency) are
currently derived from extrapolations
or theoretical modelling.30,45,57,58 Given
noted hesitations, future research should
cover this area to help generate demand
for the controlled temperature chain.
Another key refinement made to the
theory of change was identification of a
feedback loop between demand and eq-
Fig. 3. Revised context–mechanism–outcome construct for the theory of change of controlled temperature chain for vaccination in
low- and middle-income countries
Context
Theory of change domain 1
Theory of change domain 2
Theory of change domain 3
Theory of change domain 4
Demand and uptake of the
controlled temperature chain
Controlled temperature chain
compliance and safe
implementation
Improved efficiency of
vaccination programmes
Improved equitable
coverage
A history of reliance on standard
cold chain logistics; and a lack of
experience with vaccine use
outside the standard cold chain
Special vaccination programmes
(school campaign, outbreak
response and birth dose
vaccination)
Adequately trained vaccinators
working in special vaccination
programmes
Populations with restricted access
to vaccinations, or historically low
vaccination coverage
Awareness of relevant cold chain
constraints in different settings
Guidance and training provided to
vaccination workers on correct
controlled temperature chain
practices
No sourcing preparation or
conditioning of ice-packs reduces
the risk of vaccine freezing
Understanding of, and compliance
with, controlled temperature
chain protocols by local
vaccination workers
Awareness of the controlled
temperature chain as an available
intervention for relevant
vaccination programmes
Mechanism(s)
National and global policy-makers
able to identify use cases that
would benefit from the controlled
temperature chain, including use
alongside existing health
programmes
Understanding of, and compliance
with, controlled temperature
chain protocols by local
vaccination workers
Reduced dependence upon
peripheral cold chain capacity
Effort previously required for
transportation and maintenance
of cold chain redirected to
microplanning and vaccination
Reduced reliance on cold chain,
transport and lower staff burden
Evidence of safety and
effectiveness of ambiently stored
vaccines
No additional closed vial wastage
under the controlled temperature
chain when protocols are followed
Increased speed in outbreak
response, and more timely
vaccination
Overall cost-effectiveness is
improved even with increased
vaccine commodity cost
Outcome
Demand and uptake of controlled
temperature chain-licensed
vaccines
The controlled temperature chain
used compliantly and safely
within vaccination programmes
Strong evidence
Some evidence
The controlled temperature chain is
time saving
The controlled temperature chain is
cost saving
Improved equitable vaccination
coverage
No evidence
Note: Text in italics is revision of the initial theory of change in Fig. 1. Downward arrows indicate link of context–mechanism–outcome within each theory of
change domain. Horizontal arrows link domains to each other within the overall theory of change.
498
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
Systematic reviews
Controlled temperature chain for vaccination
Christopher P Seaman et al.
uitable coverage gains. We observed that
coverage gains attributable to controlled
temperature chain-relevant storage were
a driver of uptake in some experiences,
and may provide a sense of confidence
that the approach will be beneficial.
However, more studies which quantify
the direct coverage gains attributable to
a controlled temperature chain approach
are required. Demand for controlled temperature chain may increase if a causal
link can be established between coverage
gains and the approach, and not from
an enhanced effort as occurs in a pilot
study context.
Our synthesis has some key limitations. First, we limited our scope to
uptake and implementation experiences
and did not seek to include experiences
of manufacturers or developers. While
important and a potential avenue for
future research, manufacturers’ willing-
ness to develop or relicense vaccines for
the controlled temperature chain will
likely depend upon demand, a key focus
of this synthesis. Second, we cannot
exclude publication bias from synthesis
findings. We did not identify any failed
experiences. If these failures occurred,
the possibility exists they did not get
reported. Finally, realist methods are
inherently subjective, and findings could
be influenced by researcher perspectives.
In an attempt to counteract this, results
were frequently communicated to research commissioners and other experts
for cross-checking.
Synthesis of evidence from controlled temperature chain approaches
broadly supported the existing theory
of change. Credible evidence demonstrated the overall feasibility of controlled
temperature chain to improve equitable
vaccination coverage in low- and middle-
income countries, as well as supporting
that integration of the approach into
vaccination programmes is safe. Future
research should conduct use case studies for eligible vaccines and quantify
the economic and attributable coverage
benefits of the approach in a range of
health systems. ■
Acknowledgements
CPS and NS are also affiliated with the
School of Public Health and Preventive Medicine, Monash University,
Melbourne, Australia. CM is also affiliated with Burnet Institute, Melbourne,
Australia.
Funding: CPS receives support through an
Australian government Research Training Program scholarship.
Competing interests: None declared.
ملخص
جتميع ألدلة:سلسلة درجات احلرارة اخلاضعة للتحكم املتبعة للتطعيم يف الدول ذات الدخل املنخفض والدخل املتوسطة
واقعية
هذا األسلوب بني جهات تقديم اخلدمات؛ إال أن توليد مستوى
مكافئ من الطلب بني واضعي السياسات يتطلب أدلة أكرب عىل
وتعريفات حالة، ومكاسب تغطية التحصني،الفوائد االقتصادية
دعمت األدلة املتسقة سالمة األسلوب عند دجمها يف.االستخدام
ساعد كل من التدريب العميل واإلرشاف.برامج التحصني اخلاصة
كان التوفري يف.جهات تقديم اخلدمات يف االمتثال للربوتوكوالت
بينام كانت بيانات،الوقت هو الدليل الرئييس عىل مكاسب الكفاءة
تم اإلبالغ عن تغطية ُحُم ّسنة.توفري التكاليف عند حدها األدنى
الوصول،ومتكافئة حينام أتاح ختزين اللقاح خارج سلسلة التربيد
ال يوجد دليل يشري إىل.إىل السكان الذين يصعب الوصول إليهم
وال زيادة معدالت األحداث السلبية للقاحات،فعالية أقل للقاح
.التي يتم تقديمها بموجب هذا األسلوب
االستنتاج دعمت األدلة املجمعة بشكل واضح النظرية األولية
إن التعامل مع فجوات األدلة عىل الفوائد االقتصادية.للتغيري
. قد يؤدي إىل زيادة االستيعاب يف املستقبل،ومكاسب التغطية
الغرض تقييم األدلة التي تصف كيف يمكن ألسلوب التطعيم
أن يؤدي إىل حتسني،بسلسلة درجات احلرارة اخلاضعة للتحكم
تغطية التحصني املتكافئة يف الدول ذات الدخل املنخفض والدخل
.املتوسط
الطريقة لقد وضعنا نظرية لبناء التغيري من سلسلة درجات احلرارة
خارطة طريق اسرتاتيجية للقاحات ذات:اخلاضعة للتحكم
(1) : وحتتوي عىل أربعة قطاعات،2020 إىل2017 األولوية
( االمتثال واالستخدام2)استيعاب األسلوب والطلب عليه؛ و
( مكاسب الكفاءة الربناجمية من هذا3)اآلمن لألسلوب؛ و
للتحقق من.حسنة واملتكافئة
ّ ( تغطية التحصني ا ُمل4)األسلوب؛ و
قمنا بتطبيق طريقة مراجعة واقعية لتحليل،نظرية التغيري وحتسينها
،التوصيفات املنشورة لسلسلة درجات احلرارة اخلاضعة للتحكم
.أو التجارب وثيقة الصلة
ً مقا34 النتائج قمنا بتقييم
سلسلة فريدة لدرجات22 تصف،ال
أو جتارب وثيقة الصلة عرب أربع،احلــرارة اخلاضعة للتحكم
لقد حددنا طل ًبا قو ًيا عىل مثل.مناطق تابعة ملنظمة الصحة العاملية
摘要
中低收入国家疫苗受控温度链 :现实主义证据综合
目的 旨在评估有关疫苗受控温度链方法如何促使中低
收入国家提高公平免疫接种率的证据。
方法 我们根据《可控温度链 :2017-2020 年优先疫苗
战略路线图》创建了包含以下四个领域的变革理论 :
(i) 对该方法的理解和要求 ;(ii) 该方法的合规性和安
全使用 ;(iii) 该方法带来的计划性效率提高 ;以及 (iv)
提高公平免疫接种率。为了验证和改进该变革理论,
我们采用现实主义综述方法来分析描述受控温度链或
密切相关经验的已公布信息。
结果 我们评估了 34 篇文章,了解了世界卫生组织四
个地区的 22 种独特的受控温度链或密切相关经验。
我们发现服务提供商强烈要求采用这种方法 ;但是,
如要促使同样多的政策制定者认同此类需求,则需要
有更多的证据来证明经济效益以及疫苗接种率提高和
用例定义。证据一致性表明将该方法纳入特殊疫苗接
种计划时能够确保安全性。切实可行的培训和监督支
持提供商遵守协议。节省时间是表明效率提高的主要
依据,但成本节约相关数据很少。据报道,如果非冷
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
499
Systematic reviews
Christopher P Seaman et al.
Controlled temperature chain for vaccination
链存储疫苗能够供难以触及的人群使用,则可提高公
平接种率。并无任何证据表明采用该方法提供的疫苗
效果较差或不良事件发生率升高。
结论 综合证据广泛支持初始变革理论。解决经济效益
和接种率升高方面的证据差距可能会导致未来采用率
提高。
Résumé
Chaîne de température contrôlée pour la vaccination dans les pays à revenu faible et intermédiaire: synthèse réaliste fondée
sur les preuves
Objectif Évaluer les preuves exposant la manière dont la chaîne de
température contrôlée pourrait constituer l'approche idéale pour
garantir une couverture vaccinale plus équitable dans les pays à revenu
faible et intermédiaire.
Méthodes Nous avons élaboré un concept basé sur la théorie du
changement figurant dans Chaîne de température contrôlée: feuille de
route stratégique pour les vaccins prioritaires 2017–2020, et portant sur
quatre domaines: (i) demande et adhésion à l'approche; (ii) respect
et sécurité d'utilisation de l'approche; (iii) avantages de l'approche au
niveau de l'efficacité des programmes; et enfin, (iv) couverture vaccinale
plus équitable. Afin de vérifier et d'affiner la théorie du changement,
nous avons employé une méthode de synthèse réaliste destinée à
analyser les descriptions publiées concernant la chaîne de température
contrôlée ou toute autre expérience étroitement liée au sujet.
Résultats Nous avons examiné 34 articles décrivant 22 chaînes de
température contrôlée ou d'autres expériences similaires dans quatre
régions de l'Organisation mondiale de la Santé. Nous avons identifié
une forte demande pour cette approche chez les fournisseurs de
services; cependant, pour déclencher une demande identique chez les
législateurs, il faut plus d'arguments axés sur les retombées économiques
et l'amélioration de la couverture vaccinale, ainsi que des définitions de
cas d'utilisation. De nombreux éléments probants ont confirmé que
l'approche était sûre lorsqu'elle est intégrée dans des programmes de
vaccination spéciaux. Assurer un niveau de formation et de supervision
acceptable a permis aux fournisseurs de se conformer aux protocoles.
Le gain de temps est le principal atout en termes d'efficacité, tandis
que les données sur la réduction des coûts sont limitées. Stocker les
vaccins au-delà de la chaîne du froid a rendu la couverture vaccinale
plus équitable car les populations difficiles à atteindre ont ainsi pu y
avoir accès. Rien n'a permis d'indiquer une diminution de l'efficacité
des vaccins ou un taux d'effets indésirables plus élevé pour les vaccins
fournis dans le cadre de cette approche.
Conclusion La synthèse des preuves a largement corroboré la théorie du
changement. Apporter des arguments supplémentaires pour démontrer
ses bienfaits en matière d'économie et de couverture vaccinale pourrait
favoriser l'adhésion.
Резюме
Система с регулируемой температурой для вакцинации в странах с низким и средним уровнем дохода:
обобщение реалистичных фактических данных
Цель Оценить фактические данные, описывающие, как подход
к вакцинации в рамках системы с регулируемой температурой
может привести к обеспечению справедливого охвата
иммунизацией в странах с низким и средним уровнем дохода.
Методы Авторы создали теорию преобразований на основе
системы с регулируемой температурой: стратегический план
для приоритетных вакцин на 2017–2020 гг. для четырех областей:
(i) восприятие подхода и спрос на него; (ii) соблюдение и безопасное
использование подхода; (iii) повышение эффективности программ
благодаря этому подходу; (iv) улучшенный справедливый
охват иммунизацией. Чтобы проверить и улучшить теорию
преобразований, авторы применили метод реалистичного
обзора для анализа опубликованных описаний системы с
регулируемой температурой или подобного опыта.
Результаты Авторы проанализировали 34 статьи, описывающие
22 уникальные системы с регулируемой температурой или
подобный опыт в четырех регионах Всемирной организации
здравоохранения. Авторы выявили высокий спрос на такой
подход среди поставщиков услуг, однако для создания
равного уровня спроса со стороны лиц, ответственных за
разработку политики, требуется больше фактических данных об
экономической пользе и увеличении охвата вакцинацией, а также
определении сценариев. Убедительные данные подтверждают
безопасность этого подхода при его включении в специальные
программы по вакцинации. Поставщикам услуг предоставлялось
возможное обучение и контроль при соблюдении протоколов.
Данные об экономии времени были основными данными
повышения эффективности, в то время как данные об экономии
расходов были минимальными. Сообщалось об улучшении
справедливого охвата там, где хранение вакцин за пределами
холодовой цепи обеспечивало доступ к труднодоступным
группам населения. Нет данных, указывающих на более низкую
эффективность вакцины или повышенную частоту нежелательных
явлений для вакцин, вводимых в рамках данного подхода.
Вывод Объединенные данные в целом поддерживают
первоначальную теорию преобразований. Устранение пробелов
в фактических данных об экономической пользе и расширении
охвата может увеличить вероятность использования подхода в
будущем.
Resumen
Cadena de temperatura controlada para la vacunación en países de ingresos bajos y medios: una síntesis realista sobre las pruebas
Objetivo Evaluar las pruebas que describen cómo el enfoque de la
cadena de temperatura controlada para la vacunación podría suponer
una mejora de la cobertura de inmunización equitativa en los países
de ingresos bajos y medios.
500
Métodos Se creó un constructo de teoría del cambio a partir de la
Cadena de temperatura controlada: hoja de ruta estratégica para las
vacunas prioritarias 2017-2020, que contiene cuatro dominios: (i)
adopción y demanda del enfoque; (ii) cumplimiento y uso seguro
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
Systematic reviews
Controlled temperature chain for vaccination
Christopher P Seaman et al.
del enfoque; (iii) beneficios del enfoque en términos de eficacia del
programa; y (iv) mejora de la cobertura de inmunización equitativa.
Para verificar y mejorar la teoría del cambio, se aplicó un método de
revisión realista para analizar las descripciones publicadas de la cadena
de temperatura controlada o de experiencias muy relacionadas.
Resultados Se evaluaron 34 artículos, que describían 22 experiencias
específicas de cadena de temperatura controlada o muy relacionadas en
cuatro regiones de la Organización Mundial de la Salud. Se identificó una
fuerte demanda de este enfoque entre los prestadores de servicios; sin
embargo, para generar un nivel igual de demanda entre los responsables
de formular políticas se requieren mayores pruebas sobre los beneficios
económicos y de la cobertura de vacunación, así como definiciones
de casos de uso. Las pruebas consistentes apoyan la seguridad del
enfoque cuando se integra en programas especiales de vacunación.
La formación y la supervisión factibles ayudaron a los prestadores a
cumplir los protocolos. El ahorro de tiempo fue la principal prueba de
los beneficios de eficiencia, mientras que los datos de ahorro de costes
fueron mínimos. Se informó de una mayor cobertura equitativa cuando
el almacenamiento de vacunas más allá de la cadena de frío permitió
el acceso a poblaciones de difícil acceso. No hay pruebas que indiquen
una menor eficacia de las vacunas ni un aumento de las tasas de efectos
adversos de las vacunas suministradas mediante este enfoque.
Conclusión La síntesis de las pruebas apoyaron ampliamente la teoría
inicial del cambio. Resolver las deficiencias de las pruebas sobre los
beneficios económicos y de cobertura podría aumentar su adopción
en el futuro.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Next-generation immunization supply chains are needed to improve health
outcomes. Seattle: PATH; 2015. Available from: https://path.azureedge.net/
media/documents/APP_isc_key_messages_rptv2.pdf [cited 2021 May 6].
Controlled temperature chain: strategic roadmap for priority vaccines
2017–2020. Geneva: World Health Organization; 2017. Available from:
https://apps.who.int/iris/handle/10665/272994 [cited 2020 Jun 18].
Patel MK, Kahn A-L. Game changing: hepatitis B vaccine in a controlled
temperature chain. Lancet Glob Health. 2018 Jun;6(6):e596–7. doi: http://dx
.doi.org/10.1016/S2214-109X(18)30233-X PMID: 29773113
Zipursky S, Djingarey MH, Lodjo J-C, Olodo L, Tiendrebeogo S, Ronveaux
O. Benefits of using vaccines out of the cold chain: delivering meningitis A
vaccine in a controlled temperature chain during the mass immunization
campaign in Benin. Vaccine. 2014 Mar 14;32(13):1431–5. doi: http://dx.doi
.org/10.1016/j.vaccine.2014.01.038 PMID: 24559895
Kahn AL, Kristensen D, Rao R. Extending supply chains and improving
immunization coverage and equity through controlled temperature chain
use of vaccines. Vaccine. 2017 Apr 19;35(17):2214–6. doi: http://dx.doi.org/
10.1016/j.vaccine.2016.10.091 PMID: 28364934
Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist synthesis: an
introduction. Manchester: ESRC Research Methods Programme, University
of Manchester; 2004.
Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review–a new method
of systematic review designed for complex policy interventions. J Health
Serv Res Policy. 2005 Jul;10 Suppl 1:21–34. doi: http://dx.doi.org/10.1258/
1355819054308530 PMID: 16053581
Suggested risk of bias criteria for EPOC reviews. CITY: Cochrane Effective
Practice and Organisation of Care (EPOC); YEAR. Available from: https://
epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources
-for-authors2017/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf
[cited 2020 Aug 15].
CASP Checklist: 10 questions to help you make sense of a qualitative
research. Oxford: Critical Appraisal Skills Programme; 2018. Available from:
https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative
-Checklist-2018.pdf [cited 2020 Aug 15].
Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for
assessment of methodological quality of economic evaluations: Consensus
on Health Economic Criteria. Int J Technol Assess Health Care. 2005
Spring;21(2):240–5. doi: http://dx.doi.org/10.1017/S0266462305050324
PMID: 15921065
SURE Guides for Preparing and Using Evidence-Based Policy Briefs. CITY:
SURE Collaboration; 2011. Available from: https://epoc.cochrane.org/sites/
epoc.cochrane.org/files/public/uploads/SURE-Guides-v2.1/Collectedfiles/
sure_guides.html [cited 2020 Oct 6].
Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al.
Guidance on the conduct of narrative synthesis in systematic reviews. A
product from the ESRC methods programme Version. Lancaster: Lancaster
University; 2006. doi: http://dx.doi.org/10.13140/2.1.1018.4643
Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic
review and synthesis of evidence for international development policy and
practice. J Dev Effect. 2012;4(3):409–29. doi: http://dx.doi.org/10.1080/
19439342.2012.710641
Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES
publication standards: realist syntheses. BMC Med. 2013 Jan 29;11(1):21.
doi: http://dx.doi.org/10.1186/1741-7015-11-21 PMID: 23360677
15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et
al. Updating guidance for reporting systematic reviews: development of the
PRISMA 2020 statement. J Clin Epidemiol. 2021 Jun;134:103–12. doi: http://
dx.doi.org/10.1016/j.jclinepi.2021.02.003 PMID: 33577987
16. Sutanto A, Suarnawa IM, Nelson CM, Stewart T, Soewarso TI. Home
delivery of heat-stable vaccines in Indonesia: outreach immunization
with a prefilled, single-use injection device. Bull World Health Organ.
1999;77(2):119–26. PMID: 10083709
17. Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaya A, et al. At-birth
immunisation against hepatitis B using a novel pre-filled immunisation
device stored outside the cold chain. Vaccine. 1999 Oct 14;18(5-6):498–502.
doi: http://dx.doi.org/10.1016/S0264-410X(99)00242-X PMID: 10519939
18. Levin CE, Nelson CM, Widjaya A, Moniaga V, Anwar C. The costs of home
delivery of a birth dose of hepatitis B vaccine in a prefilled syringe in
Indonesia. Bull World Health Organ. 2005 Jun;83(6):456–61. PMID:
15976897
19. Petit D, Tevi-Benissan C, Woodring J, Hennessey K, Kahn A-L. Countries’
interest in a hepatitis B vaccine licensed for the controlled temperature
chain; survey results from African and Western Pacific regions. Vaccine. 2017
Dec 14;35(49) 49 Pt B:6866–71. doi: http://dx.doi.org/10.1016/j.vaccine
.2017.10.025 PMID: 29132994
20. Breakwell L, Anga J, Dadari I, Sadr-Azodi N, Ogaoga D, Patel M. Evaluation of
storing hepatitis B vaccine outside the cold chain in the Solomon Islands:
Identifying opportunities and barriers to implementation. Vaccine. 2017
May 15;35(21):2770–4. doi: http://dx.doi.org/10.1016/j.vaccine.2017.04.011
PMID: 28431814
21. Wang L, Li J, Chen H, Li F, Armstrong GL, Nelson C, et al. Hepatitis B
vaccination of newborn infants in rural China: evaluation of a villagebased, out-of-cold-chain delivery strategy. Bull World Health Organ. 2007
Sep;85(9):688–94. doi: http://dx.doi.org/10.2471/BLT.06.037002 PMID:
18026625
22. Kolwaite AR, Xeuatvongsa A, Ramirez-Gonzalez A, Wannemuehler K,
Vongxay V, Vilayvone V, et al. Hepatitis B vaccine stored outside the
cold chain setting: a pilot study in rural Lao PDR. Vaccine. 2016 Jun
14;34(28):3324–30. doi: http://dx.doi.org/10.1016/j.vaccine.2016.03.080
PMID: 27040399
23. Hipgrave DB, Tran TN, Huong VM, Dat DT, Nga NT, Long HT, et al.
Immunogenicity of a locally produced hepatitis B vaccine with the birth
dose stored outside the cold chain in rural Vietnam. Am J Trop Med Hyg.
2006 Feb;74(2):255–60. doi: http://dx.doi.org/10.4269/ajtmh.2006.74.255
PMID: 16474080
24. Li X, Heffelfinger J, Wiesen E, Diorditsa S, Valiakolleri J, Nikuata AB, et al.
Improving hepatitis B birth dose coverage through village health volunteer
training and pregnant women education. Vaccine. 2017 Aug 3;35(34):4396–
401. doi: http://dx.doi.org/10.1016/j.vaccine.2017.06.056 PMID: 28688784
25. Nelson C, Widjaya A, Wittet S. Using Uniject™ to increase the safety and
effectiveness of hepatitis B immunization. Occasional paper no. 6. Seattle:
PATH; 2002.
26. Huong VM, Hipgrave D, Hills S, Nelson C, Hien DS, Cuong N. Out-of-coldchain delivery of the Hepatitis B birth dose in four districts of Vietnam.
Seattle: PATH; 2006. Available from: https://path.azureedge.net/media/
documents/TS_hepb_coldchain_vietnam.pdf [cited 2020 Oct 7].
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696
501
Systematic reviews
Christopher P Seaman et al.
Controlled temperature chain for vaccination
27. Study summary: evaluation of out-of-the-cold-chain approaches for
improving on-time delivery of the hepatitis B birth dose in rural areas of
China. Seattle: PATH; 2005. Available from: https://path.azureedge.net/
media/documents/TS_hepB_coldchain_china.pdf [cited 2020 Oct 7].
28. Morgan C, Rahadi A. Cost and outcomes analysis - improving immunisation
and newborn survival at the aid post level in Papua New Guinea.
Melbourne: Burnet Institute; 2011.
29. Morgan C, Bisibisera L, Bauze A. Improving immunisation and newborn
survival at the aid post level in Papua New Guinea. Melbourne: Burnet
Institute; 2010.
30. Mvundura M, Lydon P, Gueye A, Diaw IK, Landoh DE, Toi B, et al. An
economic evaluation of the controlled temperature chain approach for
vaccine logistics: evidence from a study conducted during a meningitis A
vaccine campaign in Togo. Pan Afr Med J. 2017 Jun 23;27 Suppl 3:27. doi:
http://dx.doi.org/10.11604/pamj.supp.2017.27.3.12087 PMID: 29296162
31. Steffen C, Tokplonou E, Jaillard P, Dia R, Alladji MNDB, Gessner B. A field
based evaluation of adverse events following MenAfriVac® vaccine
delivered in a controlled temperature chain (CTC) approach in Benin. Pan
Afr Med J. 2014 Aug 28;18:344. PMID: 25574320
32. Landoh DE, Kahn AL, Lacle A, Adjeoda K, Saka B, Yaya I, et al. L’utilisation
de l’approche CTC: quel impact sur la couverture vaccinale lors de la
campagne préventive de vaccination contre la méningite A avec le
MenAfriVac au Togo en 2014? Pan Afr Med J. 2017 May 12;27:38. [French].
doi: http://dx.doi.org/10.11604/pamj.2017.27.38.11873 PMID: 28761614
33. Kouassi DP, Aka LBN, Bénié BVJ, Coulibaly SR, Tagodé DB, Coulibaly D, et al.
Practice of controlled temperature chain (CTC) technique during a mass
vaccination campaign in Côte d’Ivoire. World J Vaccines. 2016;6(1):16–22.
doi: http://dx.doi.org/10.4236/wjv.2016.61003
34. Using the HPV vaccine in a controlled temperature chain (CTC) in Uganda a pilot project. Geneva: World Health Organization; 2018.
35. Khan AI, Islam MS, Islam MT, Ahmed A, Chowdhury MI, Chowdhury F, et al.
Oral cholera vaccination strategy: self-administration of the second dose in
urban Dhaka, Bangladesh. Vaccine. 2019 Feb 4;37(6):827–32. doi: http://dx
.doi.org/10.1016/j.vaccine.2018.12.048 PMID: 30639459
36. Halm A, Yalcouyé I, Kamissoko M, Keïta T, Modjirom N, Zipursky S, et
al. Using oral polio vaccine beyond the cold chain: a feasibility study
conducted during the national immunization campaign in Mali. Vaccine.
2010 Apr 26;28(19):3467–72. doi: http://dx.doi.org/10.1016/j.vaccine.2010
.02.066 PMID: 20197147
37. Juan-Giner A, Domicent C, Langendorf C, Roper MH, Baoundoh P, Fermon F,
et al. A cluster randomized non-inferiority field trial on the immunogenicity
and safety of tetanus toxoid vaccine kept in controlled temperature chain
compared to cold chain. Vaccine. 2014 Oct 29;32(47):6220–6. doi: http://dx
.doi.org/10.1016/j.vaccine.2014.09.027 PMID: 25261378
38. Grandesso F, Rafael F, Chipeta S, Alley I, Saussier C, Nogareda F, et al. Oral
cholera vaccination in hard-to-reach communities, Lake Chilwa, Malawi.
Bull World Health Organ. 2018 Dec 1;96(12):817–25. doi: http://dx.doi.org/
10.2471/BLT.17.206417 PMID: 30505029
39. Heyerdahl LW, Ngwira B, Demolis R, Nyirenda G, Mwesawina M, Rafael F, et
al. Innovative vaccine delivery strategies in response to a cholera outbreak
in the challenging context of Lake Chilwa. A rapid qualitative assessment.
Vaccine. 2018 Oct 22;36(44):6491–6. doi: http://dx.doi.org/10.1016/j.vaccine
.2017.10.108 PMID: 29126808
40. Porta MI, Lenglet A, de Weerdt S, Crestani R, Sinke R, Frawley MJ, et al.
Feasibility of a preventive mass vaccination campaign with two doses of
oral cholera vaccine during a humanitarian emergency in South Sudan.
Trans R Soc Trop Med Hyg. 2014 Dec;108(12):810–15. doi: http://dx.doi.org/
10.1093/trstmh/tru153 PMID: 25311798
41. Kristensen DD, Lorenson T, Bartholomew K, Villadiego S. Can thermostable
vaccines help address cold-chain challenges? Results from stakeholder
interviews in six low- and middle-income countries. Vaccine. 2016 Feb
10;34(7):899–904. doi: http://dx.doi.org/10.1016/j.vaccine.2016.01.001
PMID: 26778422
42. Ciglenecki I, Sakoba K, Luquero FJ, Heile M, Itama C, Mengel M, et al.
Feasibility of mass vaccination campaign with oral cholera vaccines in
response to an outbreak in Guinea. PLoS Med. 2013;10(9):e1001512. doi:
http://dx.doi.org/10.1371/journal.pmed.1001512 PMID: 24058301
43. Ladner J, Besson M-H, Audureau E, Rodrigues M, Saba J. Experiences and
lessons learned from 29 HPV vaccination programs implemented in 19
low and middle-income countries, 2009–2014. BMC Health Serv Res. 2016
Oct 13;16(1):575. doi: http://dx.doi.org/10.1186/s12913-016-1824-5 PMID:
27737666
502
44. Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, et al. Use of
Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med. 2014 May
29;370(22):2111–20. doi: http://dx.doi.org/10.1056/NEJMoa1312680 PMID:
24869721
45. Lydon P, Zipursky S, Tevi-Benissan C, Djingarey MH, Gbedonou P, Youssouf
BO, et al. Economic benefits of keeping vaccines at ambient temperature
during mass vaccination: the case of meningitis A vaccine in Chad. Bull
World Health Organ. 2014 Feb 1;92(2):86–92. doi: http://dx.doi.org/10
.2471/BLT.13.123471 PMID: 24623901
46. Mvundura M, Frivold C, Janik Osborne A, Soni P, Robertson J, Kumar S, et al.
Vaccine innovation prioritisation strategy: findings from three countrystakeholder consultations on vaccine product innovations. Vaccine. 2021
Dec 3;39(49):7195–207. doi: http://dx.doi.org/10.1016/j.vaccine.2021.08
.024 PMID: 34412922
47. Quiroga R, Halkyer P, Gil F, Nelson C, Kristensen D. A prefilled injection
device for outreach tetanus immunization by Bolivian traditional birth
attendants. Rev Panam Salud Publica. 1998 Jul;4(1):20–5. doi: http://dx.doi
.org/10.1590/S1020-49891998000700004 PMID: 9734224
48. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine
implementation in low and middle-income countries (LMICs): health
system experiences and prospects. Vaccine. 2013 Aug 20;31(37):3811–17.
doi: http://dx.doi.org/10.1016/j.vaccine.2013.06.016 PMID: 23777956
49. Seaman CP, Kahn AL, Kristensen D, Steinglass R, Spasenoska D, Scott N, et
al. Supplemental information for: Use of the controlled-temperature chain
for vaccination in low and middle-income countries– a realist evidence
synthesis of uptake and impact determinants [data repository]. Meyrin:
Zenodo; 2022. doi: http://dx.doi.org/10.5281/zenodo.6583035doi: http://dx
.doi.org/10.5281/zenodo.6583035
50. Berlier M, Barry R, Shadid J, Sirica C, Brunier A, Hasan H, et al.
Communication challenges during the development and introduction of a
new meningococcal vaccine in Africa. Clin Infect Dis. 2015 Nov 15;61 Suppl
5:S451–8. doi: http://dx.doi.org/10.1093/cid/civ493 PMID: 26553674
51. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis:
the risk of mother-to-child transmission of hepatitis B virus infection in
sub-Saharan Africa. Aliment Pharmacol Ther. 2016 Nov;44(10):1005–17. doi:
http://dx.doi.org/10.1111/apt.13795 PMID: 27630001
52. de Villiers MJ, Nayagam S, Hallett TB. The impact of the timely birth dose
vaccine on the global elimination of hepatitis B. Nat Commun. 2021 Oct
28;12(1):6223. doi: http://dx.doi.org/10.1038/s41467-021-26475-6 PMID:
34711822
53. Preventing mother-to-child transmission of hepatitis B: operational field
guidelines for delivery of the birth dose of hepatitis B vaccine. Geneva:
World Health Organization; 2006. Available from: https://apps.who.int/iris/
handle/10665/272905. [cited 2022 May 25].
54. Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. Freezing
temperatures in the vaccine cold chain: a systematic literature review.
Vaccine. 2007 May 16;25(20):3980–6. doi: http://dx.doi.org/10.1016/j
.vaccine.2007.02.052 PMID: 17382434
55. Ren Q, Xiong H, Li Y, Xu R, Zhu C. Evaluation of an outside-the-cold-chain
vaccine delivery strategy in remote regions of western China. Public
Health Rep. 2009 Sep-Oct;124(5):745–50. doi: http://dx.doi.org/10.1177/
003335490912400517 PMID: 19753953
56. Nelson C, Froes P, Dyck AM, Chavarría J, Boda E, Coca A, et al. Monitoring
temperatures in the vaccine cold chain in Bolivia. Vaccine. 2007 Jan
5;25(3):433–7. doi: http://dx.doi.org/10.1016/j.vaccine.2006.08.017 PMID:
17000036
57. Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, et al.
Cost-effectiveness of the controlled temperature chain for the hepatitis B
virus birth dose vaccine in various global settings: a modelling study. Lancet
Glob Health. 2018 Jun;6(6):e659–67. doi: http://dx.doi.org/10.1016/S2214
-109X(18)30219-5 PMID: 29773122
58. Seaman CP, Morgan C, Howell J, Xiao Y, Spearman CW, Sonderup M, et al.
Use of controlled temperature chain and compact prefilled auto-disable
devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs:
a modelling and cost-optimisation study. Lancet Glob Health. 2020
Jul;8(7):e931–41. doi: http://dx.doi.org/10.1016/S2214-109X(20)30231-X
PMID: 32562649
Bull World Health Organ 2022;100:491–502| doi: http://dx.doi.org/10.2471/BLT.21.287696